Latest Fuzeon Stories

Using mathematical concepts, Princeton researchers have developed a method of discovering new drugs for a range of diseases by calculating which physical properties of biological molecules may predict their effectiveness as medicines.The technique already has identified several potential new drugs that were shown to be effective for fighting strains of HIV by researchers at Johns Hopkins University."The power of this is that it's a general method," said Princeton chemical and...

Publishing in PLoS Pathogens, researchers at from the Kimmel Cancer Center at Jefferson have found a novel mechanism by which drugs block HIV-1 from entering host cells.Cellular invasion by HIV-1 requires the concerted action of two proteins on the viral surface: gp120 and gp41. The function of gp41 is to get the viral contents into the interior of the host cells. This requires the association of two distinct regions of gp41 called N-HR and C-HR. Anti-HIV-1 agents known as fusion inhibitors...

Although once praised for its efficacy even in highly treatment-experienced patients, Fuzeon's high cost and cumbersome mode of administration have restricted its overall growth. Driven by the launch of three new orally available and relatively inexpensive drugs, global sales of Trimeris' HIV drug have now dropped by 38% in the third quarter of 2008. Trimeris announced worldwide net sales of its HIV entry inhibitor Fuzeon for the third quarter of 2008 were $45.5 million, down 38% from $73.9...